KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) EBIAT (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBIAT data on record, last reported at $844.6 million in Q4 2025.

  • For Q4 2025, EBIAT fell 7.97% year-over-year to $844.6 million; the TTM value through Dec 2025 reached $4.5 billion, up 2.09%, while the annual FY2025 figure was $4.5 billion, 2.09% up from the prior year.
  • EBIAT reached $844.6 million in Q4 2025 per REGN's latest filing, down from $1.5 billion in the prior quarter.
  • Across five years, EBIAT topped out at $3.1 billion in Q2 2021 and bottomed at $722.0 million in Q1 2024.
  • Average EBIAT over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for EBIAT: skyrocketed 245.36% in 2021, then plummeted 72.5% in 2022.
  • A 5-year view of EBIAT shows it stood at $1.6 billion in 2021, then decreased by 26.66% to $1.2 billion in 2022, then dropped by 3.13% to $1.2 billion in 2023, then decreased by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $844.6 million in Q4 2025, $1.5 billion in Q3 2025, and $1.4 billion in Q2 2025.